Join to access to all OVN content. Join for Free
MSL Certification Programs: To Cert or Not to Cert?
MSL certification BCMAS credential MSL-BC program BC-MSL certification Medical Science Liaison training

MSL Certification Programs: To Cert or Not to Cert?


Share This Article


Summary

In this episode, Tom Caravela delves into the world of certification programs for Medical Science Liaisons (MSLs). He provides an overview of popular certifications like BCMAS and MSL-BC, as well as the BC-MSL certification from FSTP. Tom discusses the significance of these programs and how they can enhance the credibility and career prospects of MSLs. He also shares valuable resources for those considering certification and offers closing advice on making the most of these opportunities. The episode wraps up with a reminder to share the podcast and subscribe for future insights.

By request, this episodes breaks down the different MSL certification programs.

Learn…

👉 Who is eligible for which certification program

👉 What costs are associated

👉 How the programs are administered

👉 Why you may want to consider a certification

Click for Source
MSL certification, BCMAS credential, MSL-BC program, BC-MSL certification, Medical Science Liaison training

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
The ULTIMATE Checklist for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Samantha Buckley

The ULTIMATE Checklist for New MSLs

Podcast
Repackage what you have for what you want
Partner Avatar MSL Talk: Tom Caravela, Cherie Hyder

Repackage what you have for what you want

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Explore OVN